RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:71505

Cancer-associated retinopathy

high confidenceDisorder

Also known as: CAR syndrome · Paraneoplastic retinopathy

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

989

82.8th percentile

Trials

0

Interventional, condition-specific

Researchers

1,010

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare paraneoplastic disease of the eye characterized by the presence of extraocular malignancy and circulating autoantibodies against retinal proteins.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

paraneoplastic retinopathy

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    989 matched papers (471 in last 10 years) Source

  3. Phenotype characterisedPresent

    37 HPO annotations (e.g. Visual loss; Photophobia; Reduced visual acuity) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

37

Associated phenotypes · MONDO:0019112

  • Visual loss
  • Photophobia
  • Reduced visual acuity
  • Adult-onset night blindness
  • ERG: Reduced dark-adapted b-wave amplitude

Showing 5 of 37 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

989

989 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

989 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

471 in the last 10 years · high confidence · 82.8th percentile (publications denominator)

Phrase hits: 989 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,010

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Sobrin L7 papers · 2026

    a Department of Ophthalmology , Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , Massachusetts , USA .

    Papers in Europe PMC
  2. 02
    Ueno S5 papers · 2021

    Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya City, Aichi, 466-8550, Japan, ueno@med.nagoya-u.ac.jp.

    Papers in Europe PMC
  3. 03
    Adamus G3 papers · 2025

    Ocular Immunology Laboratory, Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239, USA.

    Papers in Europe PMC
  4. 04
    Dimopoulos MA3 papers · 2024

    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.

    Papers in Europe PMC
  5. 05
    Hayashi T3 papers · 2021

    Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan. taka@jikei.ac.jp.

    Papers in Europe PMC
  6. 06
    Kondo M3 papers · 2021

    Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.

    Papers in Europe PMC
  7. 07
    Liu R3 papers · 2026

    Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.

    Papers in Europe PMC
  8. 08
    Terasaki H3 papers · 2019

    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

    Papers in Europe PMC
  9. 09
    Andrikopoulou A2 papers · 2023

    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.

    Papers in Europe PMC
  10. 10
    Androudi S2 papers · 2025

    Department of Ophthalmology, University of Thessaly, 41110 Larissa, Greece.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 41 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (40)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Cancer-associated retinopathy — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Cancer-associated retinopathy" OR "CAR syndrome" OR "Paraneoplastic retinopathy"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Paraneoplastic Syndromes, Ocular

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cancer-associated retinopathy" OR "CAR syndrome" OR "Paraneoplastic retinopathy" OR "Paraneoplastic Syndromes, Ocular"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T01:42:00.991Z